Paul A. Ford

Mechelen-bovelingen, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.

Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.

Journal: ERJ open research
Published: July 01, 2025

Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis-Reply.

Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis-Reply.

Journal: JAMA
Published: September 12, 2023

An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis.

An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis.

Journal: ERJ open research
Published: August 30, 2023

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.

Journal: JAMA
Published: May 09, 2023

A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.

A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: June 09, 2022

Autotaxin facilitates selective LPA receptor signaling.

Autotaxin facilitates selective LPA receptor signaling.

Journal: Cell chemical biology
Published: March 24, 2022

GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.

GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.

Journal: The European respiratory journal
Published: March 07, 2022

Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis.

Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis.

Journal: Contemporary clinical trials
Published: September 25, 2020

The autotaxin-lysophosphatidic acid pathway mediates mesenchymal cell recruitment and fibrotic contraction in lung transplant fibrosis.

The autotaxin-lysophosphatidic acid pathway mediates mesenchymal cell recruitment and fibrotic contraction in lung transplant fibrosis.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: July 26, 2020

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.

Journal: The European respiratory journal
Published: June 29, 2020

Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans.

Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans.

Journal: ERJ open research
Published: October 22, 2019

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Journal: Advances in therapy
Published: August 14, 2019
Showing 1-12 of 24

Last Updated: 09/26/2026